The Impact of THC on Pain Modulation in Fibromyalgia

Status Recruiting

Clinical Trial Summary

The objective of this cross-sectional, double-blind, placebo-controlled clinical trial is to enhance our understanding of the pain modulation mechanisms in females diagnosed with Fibromyalgia syndrome (FMS). This study is designed to address several key questions: 1. Is there a discernible difference in the effectiveness of the two prevalent pain modulation approaches, namely Conditioned Pain Modulation (CPM) and Offset Analgesia (OA), in individuals with FMS? To answer this, both FMS patients and an age- and sex-matched healthy control group will engage in these paradigms outside of the MRI scanner. 2. How does Tetrahydrocannabinol (THC) influence CPM and OA in FMS patients? Here, the study will observe the performance of FMS patients in both paradigms after receiving treatments with THC and a placebo, conducted outside the scanner. 3. What neural alterations in pain modulation circuits are triggered by THC? To investigate this, FMS patients will undergo the OA test inside the MRI scanner following both THC and placebo treatments. 4. How does THC affect resting-state brain function in FMS patients? This part of the study involves resting-state brain scans to measure changes in functional connectivity following treatments with THC and a placebo.

Clinical Trial Description

Fibromyalgia syndrome (FMS) is a condition marked by pervasive chronic pain throughout the musculoskeletal system, often accompanied by chronic sleep disturbances, fatigue, memory challenges, and more. Despite significant advancements in the understanding of pain mechanisms due to breakthroughs in neuroscience and pain medicine, current treatments for FMS fall short of providing adequate relief, leaving many patients battling ongoing pain and related symptoms. The complete pathophysiology of FMS remains elusive, but there is substantial evidence indicating the involvement of various factors, including central sensitization and impaired descending pain modulation pathways as evidenced by functional imaging studies and sensory tests such as conditioned pain modulation (CPM) and offset analgesia (OA). Given this, comprehending the pathophysiology of FMS and the mechanisms involved is crucial. Additionally, it is critical to understand how new treatments can influence pain modulation in FMS. Recent research increasingly supports the use of cannabis, particularly Tetrahydrocannabinol (THC), for alleviating chronic pain in various syndromes. Yet, there's a lack of extensive research exploring its effectiveness in randomized, double-blind trials. Exploring THC's effects in clinical pain models could enhance our understanding of pain regulation in FMS. The current study aims to deepen our understanding of sensory and neural mechanisms in FMS, employing quantitative sensory testing such as CPM and OA, and fMRI. A key objective is to ascertain the impact of THC on pain modulation in FMS within a double-blind controlled framework. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05644054
Study type	Interventional
Source	Tel Aviv Medical Center
Contact	Yara Agbaria
Phone	972522839351
Email	yaraa@tlvmc.gov.il
Status	Recruiting
Phase	N/A
Start date	January 1, 2023
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03149198` - Mat Pilates Method in the Treatment of Women With Fibromyalgia	N/A
Completed	`NCT00965081` - A Study for Adult Patients With Fibromyalgia	Phase 4
Enrolling by invitation	`NCT06100926` - Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain	N/A
Recruiting	`NCT05068791` - Psilocybin-facilitated Treatment for Chronic Pain	Early Phase 1
Recruiting	`NCT05801497` - Balneotherapy in Primary Fibromyalgia
Active, not recruiting	`NCT04422522` - Fibromyalgia During the COVID-19 Pandemic
Completed	`NCT05361577` - Exopulse Mollii Suit and Fibromyalgia	N/A
Recruiting	`NCT05754190` - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting	`NCT05941780` - Pain Phenotypes in Patients With Fibromyalgia Syndrome
Not yet recruiting	`NCT06424743` - Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training	N/A
Completed	`NCT04771260` - Understanding Health Services Delivery for Fibromyalgia
Active, not recruiting	`NCT04690400` - Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic	N/A
Enrolling by invitation	`NCT04098757` - Fibromyalgia Different Approaches: Acupuncture vs Migratens
Completed	`NCT01697254` - The CARRA Registry	N/A
Completed	`NCT00678691` - An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue	Phase 4
Recruiting	`NCT04832100` - Bio-significance of LPC16:0 in Fibromyalgia
Not yet recruiting	`NCT05688787` - Efficacy of Perineural Injection Therapy in Primary Fibromyalgia	N/A
Completed	`NCT03905486` - Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.